Table 2.
AS-30 attenuates the somatic expression of naloxone-precipitated morphine withdrawal
| Chronic treatment (morphine vs. placebo) | Two-way anova Pretreatment (AS-30 vs. vehicle) | Interaction | ||||
|---|---|---|---|---|---|---|
| Signs | F (1, 27) | P < | F (1,27) | P < | F (1,27) | P < |
| Jumping | 0.553 | n.s | 0.553 | n.s | 0.553 | n.s. |
| Wet dog shakes | 180.477 | 0.001 | 4.677 | 0.050 | 4.677 | 0.050 |
| Paw tremour | 14.766 | 0.001 | 5.203 | 0.050 | 5.203 | 0.050 |
| Sniffing | 8.105 | 0.010 | 1.269 | n.s | 1.269 | n.s. |
| Writhing | 7.727 | 0.010 | 0.003 | n.s | 0.003 | n.s. |
| Tremour | 16.086 | 0.001 | 2.380 | n.s | 2.380 | n.s. |
| Ptosis | 21.407 | 0.001 | 0.114 | n.s | 0.114 | n.s. |
| Mastication | 48.882 | 0.001 | 4.846 | 0.050 | 4.846 | n.s. |
| Teeth chattering | 30.156 | 0.001 | 4.106 | 0.050 | 4.106 | 0.050 |
| Piloerection | 233.107 | 0.001 | 92.537 | 0.001 | 92.537 | 0.050 |
| Diarrhoea | 22.605 | 0.001 | 0.560 | n.s | 0.560 | n.s. |
| Weight loss | 78.523 | 0.001 | 1.418 | n.s | 5.092 | 0.050 |
| Global score | 212.377 | 0.001 | 14.874 | 0.001 | 14.874 | 0.001 |
Two-way anova with chronic treatment (morphine vs. placebo) and pretreatment before naloxone (AS-30 vs. vehicle) as between-subjects factors. When significant interactions in pretreatment or between these two factors were observed, a subsequent post hoc test was applied.
AS-30, Antisauvagine-30.